Bridging the Gap in Immunotherapy Prediction: The AGAE Score as a Pan Cancer Biomarker for Immune Checkpoint Inhibitor Response

Ye, B.; Fan, J.; Meng, Q.; Liang, X.; Jiang, A.; Zhang, P.

doi:10.1101/2024.10.15.618438

Home/Archive/bioRxiv

bioRxiv · 10.1101/2024.10.15.618438

Bridging the Gap in Immunotherapy Prediction: The AGAE Score as a Pan Cancer Biomarker for Immune Checkpoint Inhibitor Response

Ye, B.·Fan, J.·Meng, Q.·Liang, X.·Jiang, A.·Zhang, P.

View original source ↗Export metadata ↓

Abstract

BackgroundImmune checkpoint inhibitor (ICI) therapy efficacy varies among cancer patients, necessitating precise predictive biomarkers for optimized treatment strategies. MethodsWe developed the Adaptive best subset selection algorithm and Genetic algorithm Aided Ensemble learning (AGAE) score through multi-cohort transcriptomic analysis of ICI-treated patients. The AGAE score incorporated gene-pairing, Adaptive Best Subset Selection for feature optimization, and a Genetic Algorithm for optimal basic learner identification. We explored correlations between AGAE score and immune microenvironments using multi-omics data. Potential targets were screened using 17 CRISPR datasets and validated through in vitro and in vivo experiments. ResultsThe AGAE score demonstrated robust predictive power for ICI therapy outcomes, with lower scores correlating with enhanced treatment response. The AGAE score outperformed published signatures and conventional biomarkers. Lower AGAE scores were associated with increased immune cell infiltration, higher immunogenicity, and enhanced antitumor immune activity. The CEP55 was identified as a potential key target driving immune evasion through AGAE scoring and CRISPR screening. Experimental validation showed CEP55 downregulation attenuated tumor cell malignancy and augmented ICI therapy efficacy by modulating T cell responses. ConclusionsThe AGAE score was a potent predictor of ICI therapy efficacy, facilitating refined patient stratification. CEP55s role in the tumor microenvironments immune response highlights its potential as a therapeutic target. Targeted interventions against CEP55 may improve immunotherapy precision.

Explore related subjects

cancer biology Preprint

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Ye, B., Fan, J., Meng, Q., Liang, X., Jiang, A., Zhang, P.. 2024-10-16. Bridging the Gap in Immunotherapy Prediction: The AGAE Score as a Pan Cancer Biomarker for Immune Checkpoint Inhibitor Response. https://doi.org/10.1101/2024.10.15.618438

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

Tissue resident CD4+ memory T-cells mark response to immune checkpoint inhibition in high-grade glioma

Background: Immune checkpoint inhibitors (ICI) are efficacious in many solid tumors, but response in glioma is restricted to a small subgroup. The determinants of response and resistance to ICI remain poorly understood. Methods: Here we exploit a syngeneic hypermutated high-grade glioma model with dichotomous response to combined PD-1 and CTLA-4 inhibition to unravel determinants of tumor-infiltrating T-cells driving response. Tumor-infiltrating T-cells from ICI-responsive and non-responsive tumors were analyzed by single-cell RNA and T-cell receptor sequencing and tumor-reactive T-cell receptor clonotypes were functionally validated to characterize their transcriptional phenotypes. We verify our findings in IDH1 wildtype glioblastoma patients treated with neoadjuvant pembrolizumab. Results: ICI response was associated with intratumoral clonal expansion of tumor-reactive cytotoxic T-cells and increased infiltration of CXCR6+ CD4+ tissue resident memory T-cells (Trm). CD4 stem-like memory T-cells in responding tumors demonstrated elevated interferon responses, following trajectories toward clonally expanded Trm, versus trajectories toward exhaustion in non-responsive tumors. In responsive tumors, CD4+ Trm interacted with infiltrating CXCR3+ tumor-reactive and clonally expanded, yet transcriptionally versatile cytotoxic T-cells. Probing the post neoadjuvant ICI high-grade glioma patient tissue dataset, we confirmed increased CXCR6 expression in CD4+ T cells and the association of CD4+ Trm with prolonged overall survival. Conclusion: These findings identify CD4 tissue-resident memory T-cells as determinants of ICI response in IDH1 wildtype high-grade glioma and warrant their further investigation to improve immunotherapy outcomes.

cancer biology↗

bioRxiv2026

Circadian gene-network distortion in high-risk neuroblastoma across multiple biological reference contexts

Background: The circadian clock regulates cellular homeostasis, and its disruption has been implicated in aggressive neuroblastoma, particularly in tumours harbouring MYCN- amplification. However, it remains unclear whether alterations are restricted to individual clock genes or extend to circadian gene network coordination. We therefore examined circadian clock network disruption in adverse neuroblastoma across multiple biological contexts. Methods: We estimated circadian gene network dysregulation using Delta-CCD in tumours from two neuroblastoma cohorts (SEQC n=498 and Kocak n=649), comparing clinical features associated with outcome across canonical, adrenal-tissue matched, and developmental references. Robustness was assessed by cross-cohort meta-analysis and leave-one-gene-out analyses. Cox proportional hazards models adjusted for clinical covariates assessed association between individual clock gene expression patient outcome. Results: Delta-CCD was highest in tumours classified as high-risk (study-specific definition) across reference contexts in both cohorts. MYCN-amplified tumours showed a more reference-dependent pattern, strongest in adrenal context, while stage 4 tumours showed a similar but weaker pattern. Additional analyses supported the high-risk signal as a distributed network-level alteration rather than a single-gene phenomenon. Conclusions: High-risk neuroblastoma is characterised by robust disruption of coordinated clock gene network organisation across canonical and tissue-matched references, extending beyond individual clock genes. The extent of circadian dysregulation depends on the reference state used.

cancer biology↗

bioRxiv2026

BAP1 loss and PRAME expression converge to remodel the tumor-immune ecosystem during uveal melanoma progression

Uveal melanoma (UM) is characterized by a small number of recurrent genetic alterations that determine metastatic propensity. BAP1 loss and PRAME expression define the dominant prognostic axes in UM, yet how they promote malignant progression remains unclear. We profiled 190,535 cells from normal uvea, uveal nevus, primary and metastatic UM using single-cell transcriptomics, T cell receptor sequencing, spatial transcriptomics and isogenic perturbation models. Normal melanocytes, nevus cells and UM cells formed a transcriptional continuum marked by loss of differentiation and emergence of neural crest-like, stress-responsive, hypoxic-glycolytic and immune-interacting states. BAP1 loss and PRAME expression imposed distinct but convergent immunoregulatory programs, inducing interferon and TNF-NFkB signaling and MHC-I expression, with HLA-E showing the strongest response. These alterations were accompanied by macrophage and CD8+ T cell remodeling. PRAME-enriched tumor regions formed spatially organized niches enriched for macrophages and plasma cells. These findings define BAP1 loss and PRAME expression as distinct but convergent axes of tumor-immune coevolution and nominate HLA-E as a candidate mediator of immune resistance.

cancer biology↗